Noticias y eventos de City Therapeutics, Inc. Common Stock (CTY)CTYCity Therapeutics, Inc. Common Stock

City Therapeutics and Iambic Therapeutics Successfully Debut in Market

Biotech listings continued to build momentum as City Therapeutics and Iambic Therapeutics made their market debuts, highlighting investor interest in RNA based therapies and AI enabled drug development.LATEST IPOS AND DIRECT LISTINGS:City Therapeuticsopened on October 16 at $23. The clinical-stage biotechnology company, that says it is "developing the next generation of RNA interference therapeutics," priced its upsized initial public offering of 11.11M shares of its common stock at a public offering price of $18.00 per share. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases.Iambic Therapeuticsopened on October 15 at $16.15. The clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform priced 9.375M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range.Amaeroopened on October 15 at $4.10. The U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and advanced manufacturing priced 4,705,883 shares of its common stock at an initial public offering price of $4.25 per share. Amaero intends to use up to approximately $10M of the net proceeds of the offering to purchase capital equipment over the next 12 months with the remaining proceeds to be used for general corporate purposes, including working capital, operating expenses, and research and development.RECENT SPAC IPOS:TCGX Acquisition Corp. IIopened on October 16 at $11.20. The company had priced its initial public offering of 10M shares at a price of $10.00 per share. TCGX is a special purpose acquisition company that intends to focus its search on the healthcare and healthcare-related industries, particularly in the life sciences and medical technology sectors.PERFORMANCE:Prices as of 11 am ET on Monday, October 19 -City Therapeutics – down about 6% at $21.17;Iambic Therapeutics – down almost 29% at $16.94;Amaero – up about 28% at $5.75.RECENT IPOS TO WATCH:ADARx Pharmaceuticalsis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include FireFly Robotics, Anthropic, Nscale, Altera, and Brooks Automation.Clickto see upcoming IPO calendar on TipRanks.FireFly Robotics, which designs and manufactures autonomous, all-electric robotic systems for turf and grounds environments, announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public direct listing of its common stock. The company is not selling any shares and will not receive any proceeds in the direct listing.Anthropicis now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limitedhas filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Alteraannounced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automationannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

City Therapeutics Prices IPO at $18 per Share

City Therapeutics, a clinical-stage biotechnology company that says it is "developing the next generation of RNA interference therapeutics," priced its upsized initial public offering of 11.11M shares of its common stock at a public offering price of $18.00 per share. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases.

City Therapeutics IPO Priced at $18, Expected to Open at $22

City Therapeutics indicated to open at $22, IPO priced at $18